The purposes of the study are to evaluate the Safety, Tolerability, and Immunogenicity of different dose levels of recombinant herpes zoster vaccine with 2 doses 60 days apart in healthy subjects aged 40 years and older.
Male or female subjects ≥ 40 years of age;
The subject can and fully understand the trial procedures and voluntarily sign the ICF;
The subject is in a healthy state or has stable underlying diseases according to investigator's assessment based on medical history and related physical examination results;
The subject can comply with the requirements of the protocol;
History of herpes zoster before enrollment, or close contact with a varicella/herpes zoster patient within 30 days prior to enrollment;
Previous vaccination against herpes zoster and varicella (including vaccines that have been registered or under clinical research);
Allergic to any component of the study vaccine, or history of severe allergy to any vaccination, such as anaphylactic shock, allergic laryngeal edema, anaphylactoid purpura, thrombocytopenic purpura, local allergic necrosis reaction, angioneurotic edema, etc.
History or family history of convulsions, epilepsy, and psychiatric disorders;